5 results about "Weight gain prevention" patented technology

Use of Mycobacterium vaccae, for example strain ATCC 15483, for the treatment or prevention of weight gain, visceral adipose tissue (VAT), obesity, obesity-related metabolic diseases and stress-related disorders.

The present disclosure provides peptides for reducing weight and / or preventing weight gain comprising a GLP-1R agonist. As described herein, the GLP-1R agonist can be administered orally to a subject.

One patent obtained in the earlier stage is that the line peptide COX52-69 is cyclized to realize an oral administration route. The invention discovers that the cyclic peptide, namely C * LLPAGWV-[N-Me-Leu]-SHLDSYKKREC *, has the effect of reducing the body weight. In the invention, a diet-induced obesity (DIO) model is established by feeding C57BL / 6J mice with high-fat feed (45% of fat for energy supply) for 14 weeks. After a DIO mouse is obtained, a 17-week administration experiment is carried out by using a PBS buffer solution and a Rybelsus solution as a contrast, and observation finds that the COX52-69 cyclic peptide can relieve weight gain caused by DIO, so that the weight of the DIO mouse is reduced, and multiple metabolic indexes can be improved. Results show that the COX52-69 cyclic peptide has practical application in weight loss and weight gain prevention processes, and also has reagent application in improvement of some metabolic indexes of obese people.

Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and / or memory in a human subject.

The present disclosure provides combinations for reducing weight and / or preventing weight gain in a subject (e.g., an obese subject) comprising three or more (e.g., three or four) of: (i) an amylin analog, (ii) a GLP-1 receptor agonist, (iii) a GIP analog, and (iv) a glucagon analog. As described herein, the combination can be administered to a subject in the same pharmaceutical composition or in separate pharmaceutical compositions (e.g., via concurrent or subsequent administration).